Abstract:BackgroundBoth ketamine and methamphetamine have been used for studying the positive, negative, and cognitive symptoms, and dopaminergic and GABAergic dysfunction observed in acute schizophrenia. We aimed to explore and compare the prevalence and factor structure of psychotic symptoms in chronic ketamine and methamphetamine users.MethodsWe recruited chronic ketamine and methamphetamine users from the Guangzhou Baiyun and Kangda voluntary drug rehabilitation centres in the Hunan Province, China. All these participants met the Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria for lifetime ketamine or methamphetamine dependence determined from the Structured Clinical Interview. Participants were excluded if they met criteria for other substance dependence (excluding nicotine) at any time. All participants gave a full history of psychiatric symptoms. We used The Positive and Negative Syndrome Scale (PANSS) to assess the psychotic symptoms in these two groups. Independent sample t-tests or χ2-square test were done to determine group differences. The protocol was approved by the university ethics committee (S163, 2011).FindingsWe recruited 344 chronic ketamine users (34 were female; mean age 26·8 years, SD 5·43; mean years of education 11·6 years, SD 2·45) and 456 chronic methamphetamine users (28 were female; mean age 29·3 years SD 6·33, mean years of education 11·1 years, SD 2·78) between Jan 1, 2012, to Dec 31, 2015. 183 (53%) of 344 ketamine users and 375 (82%) of 456 methamphetamine users (χ2 t=78·37, p<0·0001) had psychiatric symptoms, with a mean duration of 23·5 months (SD 24·58) for ketamine users and 15·0 months (SD 19·42) for methamphetamine users (t=4·05, p<0·0001). The mean age when first having psychotic symptoms was 25·4 years (SD 5·55) in ketamine users and 28·5 years (6·33) in methamphetamine users (t=–5·84, p<0·0001). Mean scores on PANSS TOTAL were 52·6 (SD 23·34) in ketamine users and 61·7 (29·61) in methamphetamine users (t=–4·84, p<0·0001). Mean scores for ketamine and methamphetamine use groups on positive, negative, and general subscales were 10·8 (SD 5·45) versus 15·0 (8·26; t=–8·80, p<0·0001), 12·2 (6·91) versus 14·5 (8·68; t=–4·07, p<0·0001), and 29·7 (12·98) versus 32·2 (15·22; t=–2·55, p=0·011), respectively.InterpretationThis study provides first evidence for comparing psychotic symptoms in chronic ketamine and chronic methamphetamine users. The findings suggest that chronic methamphetamine users have higher risk of suffering from psychiatric symptoms and more severity of chronic drug-induced schizophrenia-like symptoms than do chronic ketamine users. These findings might provide some implications for pharmacological (glutamatergic and dopaminergic) models of schizophrenia.FundingNatural Science Foundation of China (81100996 to YL, and 81371480 to JT). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Prevalence and Risk Factors for Depressive Symptom in Methamphetamine Use Disorder

Differences in the prevalence and clinical correlates of depressive symptoms in male patients with methamphetamine and heroin use disorder in a Chinese Han population

Depression in Chinese men with methamphetamine dependence: Prevalence, correlates and relationship with alexithymia

Features of Psychotic Symptoms in Methamphetamine Use Disorder Patients and Ketamine Use Disorder Patients: A Cross-Sectional Study

High Prevalence of Depressive Symptoms and Impulsivity As Well As Their Relationship During Subacute Methamphetamine Withdrawal in Chronic Abusers

Relationship of Impulsivity and Depression During Early Methamphetamine Withdrawal in Han Chinese Population.

Peripheral molecular and brain structural profile implicated stress activation and hyperoxidation in methamphetamine use disorder

The influence of adverse childhood experiences and depression on addiction severity among methamphetamine users: exploring the role of perseveration

Altered Fecal Microbiota Correlated With Systemic Inflammation in Male Subjects With Methamphetamine Use Disorder

Associations of executive function and age of first use of methamphetamine with methamphetamine relapse

Dissociation of Drug and Negative Emotional Cue Induced Attentional Bias in Individuals with Methamphetamine-Use Disorder

Dynamics of intrinsic whole-brain functional connectivity in abstinent males with methamphetamine use disorder

Mapping structural covariance networks of emotional withdrawal symptoms in males with methamphetamine use disorder during abstinence

Profile of Psychiatric Symptoms in Methamphetamine Users in China: Greater Risk of Psychiatric Symptoms with a Longer Duration of Use.

Mindfulness and clinical correlates in methamphetamine use disorder

Epidemiological Characteristics and Risk Factors of Methamphetamine-Associated Psychotic Symptoms

Altered spontaneous neurological activity in methamphetamine use disorders and its association with cognitive function

The gut microbiota as a potential biomarker for methamphetamine use disorder: evidence from two independent datasets

Psychiatric Symptoms in Individuals Who Use Ketamine Versus Methamphetamine—implications for Glutamatergic and Dopaminergic Model for Schizophrenia: a Cohort Study

A Research Of Methamphetamine Induced Psychosis In 1,430 Individuals With Methamphetamine Use Disorder: Clinical Features And Possible Risk Factors

Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men